Form 4: Vir Biotechnology Director Saira Ramasastry Reports Stock Option Grant and Share Acquisition

Director Saira Ramasastry reports acquisition of shares and stock options in Vir Biotechnology.

Summary

• On May 30, 2024, Saira Ramasastry, a director of Vir Biotechnology, Inc., reported transactions involving the company's securities.
• Ramasastry acquired 8,000 shares of Common Stock at $0.
• Following the transaction, Ramasastry directly owns 18,619 shares of Common Stock.
• Ramasastry also acquired a stock option to buy 16,000 shares of Common Stock at an exercise price of $10.39, exercisable from May 30, 2025, to May 29, 2034.
• Following the transaction, Ramasastry directly owns 16,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard insider trading activity. The acquisition of shares and options could be interpreted as a positive sign, but it's a routine disclosure.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biotechnology industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates